Among post-menopausal women with angiographically documented coronary artery disease in this study, baseline cystatin C level was associated with worse clinical outcomes without accelerated progression of atherosclerosis.
Published in Brief:
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||